They also produce NRG1, which activates HER3/AKT signaling, sustaining tumor growth and conferring resistance to ADT and next-generation anti-androgens such as enzalutamide, independent of AR signaling [25,26,27]. This evidence concerns the gene ERBB3 and neoplasm.